Adlai Nortye Ltd. (ANL)
| Market Cap | 79.70M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -54.07M |
| Shares Out | 36.90M |
| EPS (ttm) | -2.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,433 |
| Open | 2.115 |
| Previous Close | 2.240 |
| Day's Range | 2.110 - 2.160 |
| 52-Week Range | 1.850 - 17.480 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 9.00 (+316.67%) |
| Earnings Date | Aug 8, 2024 |
About ANL
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recur... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ANL stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 316.67% from the latest price.
News
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focu...
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology comp...
Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles
Newly listed Adlai Nortye has yet to bring any products to market and has lost more than $130 million in just over two years. ANL's key drug candidate is a PI3K inhibitor now in global trials, even as...
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline
The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, wit...
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company fo...
U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap
There was just one pricing this past week, which was excluded from our IPO stats, while holdover biotech Adlai Nortye did not get done. Filing activity reached a six-month high in August, and six issu...
U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning...
IPO Update: Adlai Nortye Readies $72 Million U.S. IPO
Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell ...
Cancer treatment company Adlai Nortye sets terms in IPO
Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbo...
Adlai Nortye Ltd. Begins U.S. IPO Rollout
Adlai Nortye Ltd. has filed to raise $115 million in a U.S. IPO, although the final figure may differ. The firm is a clinical stage biopharma developing immunotherapy treatments for solid tumor cancer...